

**REMARKS**


Claims 1-5 and 7-14 are pending. The Examiner has required restriction to one of the following:

- I. Claims 1-4 and 8-9 drawn to a compound of Formula (I) or (IA) and a pharmaceutical composition comprising a compound of Formula (I).
- II. Claims 5, and 12-14, drawn to a process of preparing a compound of Formula (I)
- III. Claims 7, and 10-11, drawn to a method of treatment and/or prevention.

Applicants elect Group I, with traverse.

Applicants respectfully request rejoinder and full examination of the methods of treatment/prevention of group III. A search for the compounds of group I would necessarily result in discovery of any methods of treatment utilizing such compounds. Indeed, the search and examination of the compounds and their related methods of use would likely be co-extensive and, in any event, would involve such interrelated art that the search and examination of the both groups can be made without undue burden on the Examiner.

Upon election of Group I, the Examiner has required the election of a single disclosed species. Applicants respectfully elect Ethyl 1-{[7-chloro-5-(2,3-dimethoxyphenyl)-1-isobutyl-2-oxo-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]acetyl}piperidine-4-carboxylate (Example 20, Page 62).



Ethyl-1-{[7-chloro-5-(2,3-dimethoxyphenyl)-1-isobutyl-2-oxo-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]acetyl}piperidine-4-carboxylate

Claims 1-4 and 7-11 read on the elected species. (A is (C<sub>6</sub>-C<sub>10</sub>)-aryl [phenyl] substituted twice with (C<sub>1</sub>-C<sub>6</sub>)-alkoxy [both methoxy]; n is 1; R<sup>1</sup> is hydrogen; R<sup>2</sup> is halogen [chloro]; R<sup>3</sup> is (C<sub>1</sub>-C<sub>8</sub>)-alkyl [isobutyl]; R<sup>4</sup> is -OR<sup>7</sup>; and R<sup>7</sup> is (C<sub>1</sub>-C<sub>6</sub>)-alkyl [ethyl]).

The afore-mentioned elections are being made solely to comply with, and be fully responsive to, the restriction requirement set forth in the Office Action. Applicants respectfully reserve the right to pursue any non-elected or otherwise unclaimed subject matter in one or more continuation, continuation-in-part, or divisional applications.

Applicants have submitted a petition for an extension of time herewith, but believe that no additional fees are required for consideration and entry of this paper. However, Applicants authorize the Director to charge any required fee or credit any overpayment to Deposit Account No. 04-1105.

Date: **June 13, 2008**

Respectfully Submitted,

By: /Nicholas J. DiCeglie, Jr./

Nicholas J. DiCeglie, Jr.

Registration No. 51,615

Attorney for Applicant

EDWARDS ANGELL PALMER & DODGE LLP

P.O. Box 55874

Boston, MA 02205

Telephone: 212-308-4411

Facsimile: 617-227-4420